#United States #oncology #Intensity Therapeutics #Shelton #INT230-6

Financial Highlights and Progress Overview from Intensity Therapeutics

In a recent announcement, Intensity Therapeutics, Inc. reported its financial performance for the year ending December 31, 2025, revealing remarkable growth and capital acquisition amidst ongoing clinical evaluations. The company successfully raised over $20 million in gross proceeds, enhancing its financial stability with $11.9 million held in cash and equivalents, along with extending its cash runway into the second quarter of 2027.

Key Clinical Findings and Studies

One significant achievement is the publication of its study manuscript on INT230-6 in the prestigious journal eBioMedicine. This publication outlined the efficacy results from a Phase 1/2 IT-01 clinical trial involving 64 refractory metastatic cancer patients. The results showed a notable disease control rate of 75% and a median overall survival rate of 11.9 months, which is a significant improvement compared with historical data in similar patient populations.

In addition, preliminary data from the INVINCIBLE-4 Study demonstrated encouraging efficacy results for patients with early-stage operable triple-negative breast cancer. Specifically, 71.4% of patients receiving INT230-6 prior to standard of care treatment achieved a pathological complete response (pCR), compared to just 33% in the control group. Moreover, the group receiving the investigational treatment experienced fewer severe adverse events, showcasing its promise for safety and therapeutic benefit.

Plans for Future Research and Development

Moving forward, Intensity Therapeutics is focused on resuming clinical trials, particularly the INVINCIBLE-3 and INVINCIBLE-4 studies. After acquiring necessary approvals to resume patient enrollment with the support of the Swiss regulatory authorities, the company aims to catalyze further advances in its trials, optimizing treatment protocols and expanding patient outreach.

Lewis H. Bender, the company's President and CEO, expressed optimism about the future trajectory, citing the urgent need for innovative cancer treatments. He emphasized the importance of their unique approach to cancer therapy, which leverages INT230-6's ability to enhance immune recognition of tumors while minimizing toxicity.

Financial Operations Review

The financial overview indicated a reduction in operating expenses compared to the previous year, with research and development expenditures amounting to $6.8 million and general administrative costs totaling $5.2 million for 2025. This marked an overall net loss of $11.6 million, an improvement from $16.3 million in 2024, indicating effective cost management.

About INT230-6 and Intensity Therapeutics

INT230-6, the flagship candidate of Intensity Therapeutics, is designed for intratumoral injection, delivering potent chemotherapy directly to tumor sites while enhancing immune response. This innovative approach capitalizes on a proprietary DfuseRx℠ technology platform, potentially transforming the management of cancers, especially those resistant to current therapies. The company's commitment lies in developing effective, less toxic treatment options, addressing the critical unmet needs in oncology.

For additional details and updates on clinical trials and publications, visit Intensity Therapeutics’ website.